Celldex Therapeutics CLDX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $28.87M+1.8% | $28.36M-18.6% | $34.81M+18.3% | $29.43M-24.8% | ||
| $489.7M-29.7% | $696.93M+79.3% | $388.78M+41.1% | $275.52M-25.4% | ||
| $2.02M+188% | $700K-73.4% | $2.63M+657% | $347K+102% | ||
| $14.08M-33.5% | $21.18M+287% | $5.47M-55.9% | $12.39M+413% | ||
| $534.66M-28.4% | $747.16M+73.1% | $431.69M+35.9% | $317.69M-22.7% | ||
| $5.33M+22.7% | $4.35M+7.0% | $4.06M+8.4% | $3.75M+5.5% | ||
| $2.44M-37.5% | $3.9M+51.3% | $2.58M-35.6% | $4M+34.7% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $13.36M+37.0% | $9.75M+9,009% | $107K+2.9% | $104K0.0% | ||
| $582.98M-26.4% | $792.34M+70.2% | $465.63M+32.0% | $352.74M-20.7% | ||
| $1.18M-63.9% | $3.27M-6.6% | $3.49M+4.6% | $3.34M+172% | ||
| $1.23M+30.6% | $942K-76.4% | $3.99M+303% | $990K-36.3% | ||
| $1.55M+6.9% | $1.45M-10.0% | $1.61M+11.7% | $1.45M-17.2% | ||
| $50.99M+29.1% | $39.5M+26.9% | $31.13M+67.2% | $18.61M+12.6% | ||
| $784K-66.8% | $2.36M+154% | $928K-64.1% | $2.59M+99.7% | ||
| $4.04M+16.4% | $3.47M-21.1% | $4.4M-17.4% | $5.33M-27.5% | ||
| $55.82M+23.1% | $45.34M+24.4% | $36.46M+37.4% | $26.53M+5.4% | ||
| —— | —— | —— | $0— | ||
| $67K+1.5% | $66K+17.9% | $56K+19.1% | $47K0.0% | ||
| $2.34B+1.7% | $2.3B+26.1% | $1.82B+15.3% | $1.58B+1.3% | ||
| -$1.81B-16.6% | -$1.56B-11.3% | -$1.4B-11.3% | -$1.26B-9.8% | ||
| $3.63M+9.4% | $3.31M+0.2% | $3.31M+163% | $1.26M-33.5% | ||
| $527.17M-29.4% | $747.01M+74.1% | $429.17M+31.6% | $326.2M-22.2% | ||
| $582.98M-26.4% | $792.34M+70.2% | $465.63M+32.0% | $352.74M-20.7% | ||
| $489.7M-29.7% | $696.93M+79.3% | $388.78M+41.1% | $275.52M-25.4% | ||
| $13.36M+37.0% | $9.75M+9,009% | $107K+2.9% | $104K0.0% | ||
| $2.44M-37.5% | $3.9M+51.3% | $2.58M-35.6% | $4M+34.7% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $2.44M-37.5% | $3.9M+51.3% | $2.58M-35.6% | $4M+34.7% | ||
| $13.36M+37.0% | $9.75M+9,009% | $107K+2.9% | $104K0.0% | ||
| $2.44M-37.5% | $3.9M+51.3% | $2.58M-35.6% | $4M+34.7% | ||
| $13.36M+37.0% | $9.75M+9,009% | $107K+2.9% | $104K0.0% | ||
| $47.03M+39.0% | $33.84M+53.6% | $22.03M+71.6% | $12.84M+7.0% | ||
| $47.03M+39.0% | $33.84M+53.6% | $22.03M+71.6% | $12.84M+7.0% | ||
| $1.23M+30.6% | $942K-76.4% | $3.99M+303% | $990K-36.3% | ||
| $2.34M-38.7% | $3.81M+50.0% | $2.54M-37.0% | $4.03M+32.6% | ||
| $2.34B+1.7% | $2.3B+26.1% | $1.82B+15.3% | $1.58B+1.3% | ||
| $67K+1.5% | $66K+17.9% | $56K+19.1% | $47K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Celldex Therapeutics cover its short-term obligations?
- Its current ratio is 8.92 — current assets exceed current liabilities.
- Where does Celldex Therapeutics's balance sheet data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.